Rep. Gilbert Cisneros Buys Vaxcyte (PCVX) Stock
On May 12, 2026, U.S. House member Gilbert Cisneros bought shares of Vaxcyte, Inc. valued between $1,001 and $15,000.
Reviewed by automated data checks against the source filing. How we make and check alerts
Rep. Gilbert Cisneros bought between $1,001 and $15,000 of Vaxcyte, Inc. ($PCVX) stock on May 12, 2026. The trade was disclosed in a STOCK Act periodic transaction report filed June 9, 2026.
Since the trade, $PCVX is down 9.7% after 1 week, down 12.5% after 1 month and up 17.8% to date (from the $54.03 close on May 12, 2026).
Financial Disclosure Report
Clerk of the House of Representatives • Legislative Resource Center • B81 Cannon Building • Washington, DC 20515
Filer Information
- Name:
- Rep. Gilbert Cisneros (D-CA)
- Status:
- Member — House
- State/District:
- CA-31
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Jun 9, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| Vaxcyte, Inc. ($PCVX) | Buy | May 12, 2026 | $1,001 - $15,000 |
Summary of the filed report, not the original document. Find the original: House financial disclosure search
PCVX
Vaxcyte, Inc.
Key Points
- Gilbert Cisneros purchased shares of Vaxcyte (PCVX) valued between $1,001 and $15,000 on May 12, 2026, with shares trading at $47.46 on that day.
- Vaxcyte has a market capitalization of nearly $8.77 billion and operates in the healthcare sector, focusing on innovative vaccine development.
- Analysts currently maintain a strong outlook on Vaxcyte, with a consensus rating of 'strong buy' and a mean price target of $109.
Get $PCVX trade alerts by text
We text you when insiders, Congress or big funds trade $PCVX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Vaxcyte, Inc. alert may contain errors. Disclosures
Gilbert Cisneros Buys Vaxcyte Shares
On May 12, 2026, U.S. House member Gilbert Cisneros purchased shares of Vaxcyte, Inc. (NasdaqGS: PCVX) valued between $1,001 and $15,000. The shares were trading at $47.46 at that time. The transaction was disclosed on June 9, 2026, as part of periodic reports mandated by the STOCK Act.
Gilbert Cisneros vs. the S&P 500
Hypothetical returns from Gilbert Cisneros's disclosed trades, not real profit or advice. How we model this.
Timing of the Purchase
Cisneros's buy reflects a strategic entry into Vaxcyte, a company involved in advanced vaccine innovations. While the specific number of shares purchased hasn't been disclosed, the purchase amount suggests he took a significant interest in the company during this period.
Institutional Activity
No peer funds reported changes in their positions for Vaxcyte, indicating a lack of recent institutional activity that could provide further context for Cisneros's purchase.
How PCVX Stock Has Traded
The stock's price of $47.46 on the day of the purchase is well below its 52-week high of $65.00, suggesting that Cisneros may see value at this price point. Vaxcyte's shares have fluctuated significantly, with a 52-week low of $31.89, emphasizing the volatility often seen in the biotechnology sector.
Recent Earnings
Vaxcyte, Inc. is expected to announce its next earnings on November 3, 2026. As a clinical-stage vaccine company, its financial results will be closely watched for insights into its pipeline and market performance, particularly as it continues to develop its lead candidate, VAX-24, aimed at preventing invasive pneumococcal disease in infants.
Insider Buying and Selling at Vaxcyte, Inc.
Recent insider activity at Vaxcyte shows a mix of buying and selling. On June 18, 2026, CEO Grant Pickering bought 225 shares at an average price of $1.79, totaling about $402.75. However, he also sold over 23,000 shares in a planned sale, indicating varying levels of confidence among executives. Meanwhile, CFO Andrew Guggenhime executed both a planned sale of 10,000 shares worth $530,000 and a purchase of 10,000 shares valued at $53,500 on the same day.
Analysts Set New Price Targets
Analysts have a positive outlook on Vaxcyte, with multiple firms maintaining 'buy' ratings. Notably, Needham recently increased its price target from $110 to $122, while BTIG reiterated a target of $89 on October 5, 2026. The general consensus among analysts reflects confidence in the company's innovative approach and growth potential, as evidenced by a strong 'buy' rating across nine analyst opinions and a mean price target of $109.
What PCVX Does
Vaxcyte, Inc. is a clinical-stage company based in San Carlos, California, focused on developing vaccines to combat bacterial diseases. Its lead candidate, VAX-24, aims to address serious health concerns in pediatric populations. The company's innovative strategies position it well within the biotechnology sector.
What's Ahead for PCVX
Investors will be keenly watching Vaxcyte's upcoming earnings report on November 3, 2026, for updates on its financial health and progress in vaccine development. The recent purchase by Rep. Cisneros adds to the narrative of institutional interest and potential growth, although the full impact of such trades may only become clear with future market developments. Remember, the reported trades may not reflect current holdings as they are based on past transactions.
Related Filing Alerts
Source: Gilbert Cisneros's STOCK Act disclosure on $PCVX (May 12, 2026). Find the original filing: House financial disclosure search. Written by software, not financial advice. How we make alerts